{
    "company": {
        "name": "Novo Nordisk A/S",
        "cvr": "24256790",
        "industry": "Pharmaceutical",
        "founded": "1923",
        "employees": 47000,
        "description": "Global healthcare company specializing in diabetes care, obesity, and rare diseases"
    },
    "documents": {
        "profit_and_loss": {
            "2024": {
                "currency": "DKK",
                "revenue": 290000000000,
                "costOfGoodsSold": 58000000000,
                "grossProfit": 232000000000,
                "operatingExpenses": 85000000000,
                "ebit": 147000000000,
                "interestExpense": 2000000000,
                "taxExpense": 29000000000,
                "netIncome": 116000000000
            },
            "2023": {
                "currency": "DKK",
                "revenue": 232000000000,
                "costOfGoodsSold": 48000000000,
                "grossProfit": 184000000000,
                "operatingExpenses": 72000000000,
                "ebit": 112000000000,
                "interestExpense": 1800000000,
                "taxExpense": 22000000000,
                "netIncome": 88200000000
            },
            "2022": {
                "currency": "DKK",
                "revenue": 177000000000,
                "costOfGoodsSold": 38000000000,
                "grossProfit": 139000000000,
                "operatingExpenses": 58000000000,
                "ebit": 81000000000,
                "interestExpense": 1500000000,
                "taxExpense": 16000000000,
                "netIncome": 63500000000
            }
        },
        "balance_sheet": {
            "2024": {
                "currency": "DKK",
                "assets": {
                    "cash": 45000000000,
                    "accountsReceivable": 52000000000,
                    "inventory": 38000000000,
                    "totalCurrentAssets": 145000000000,
                    "propertyPlantEquipment": 95000000000,
                    "intangibleAssets": 42000000000,
                    "totalAssets": 320000000000
                },
                "liabilities": {
                    "accountsPayable": 28000000000,
                    "shortTermDebt": 15000000000,
                    "totalCurrentLiabilities": 65000000000,
                    "longTermDebt": 35000000000,
                    "totalLiabilities": 120000000000
                },
                "equity": {
                    "commonStock": 5000000000,
                    "retainedEarnings": 195000000000,
                    "totalEquity": 200000000000
                }
            },
            "2023": {
                "currency": "DKK",
                "assets": {
                    "cash": 38000000000,
                    "accountsReceivable": 42000000000,
                    "inventory": 32000000000,
                    "totalCurrentAssets": 120000000000,
                    "propertyPlantEquipment": 78000000000,
                    "intangibleAssets": 38000000000,
                    "totalAssets": 265000000000
                },
                "liabilities": {
                    "accountsPayable": 24000000000,
                    "shortTermDebt": 12000000000,
                    "totalCurrentLiabilities": 55000000000,
                    "longTermDebt": 30000000000,
                    "totalLiabilities": 100000000000
                },
                "equity": {
                    "commonStock": 5000000000,
                    "retainedEarnings": 160000000000,
                    "totalEquity": 165000000000
                }
            },
            "2022": {
                "currency": "DKK",
                "assets": {
                    "cash": 32000000000,
                    "accountsReceivable": 35000000000,
                    "inventory": 28000000000,
                    "totalCurrentAssets": 102000000000,
                    "propertyPlantEquipment": 65000000000,
                    "intangibleAssets": 35000000000,
                    "totalAssets": 225000000000
                },
                "liabilities": {
                    "accountsPayable": 20000000000,
                    "shortTermDebt": 10000000000,
                    "totalCurrentLiabilities": 48000000000,
                    "longTermDebt": 28000000000,
                    "totalLiabilities": 88000000000
                },
                "equity": {
                    "commonStock": 5000000000,
                    "retainedEarnings": 132000000000,
                    "totalEquity": 137000000000
                }
            }
        },
        "contracts": [
            {
                "type": "customer",
                "counterparty": "US Department of Veterans Affairs",
                "annualValue": 5000000000,
                "term": "5 years",
                "autoRenew": true
            },
            {
                "type": "customer",
                "counterparty": "UK National Health Service",
                "annualValue": 3500000000,
                "term": "3 years",
                "autoRenew": true
            },
            {
                "type": "supplier",
                "counterparty": "Major API Supplier",
                "annualValue": 8000000000,
                "term": "7 years",
                "autoRenew": false
            }
        ]
    },
    "stripe": null,
    "plaid": {
        "accounts": [
            {
                "type": "checking",
                "bank": "Danske Bank",
                "balance": 45000000000
            }
        ],
        "monthlyInflow": 24000000000,
        "monthlyOutflow": 18000000000
    },
    "trends": {
        "revenueGrowth": [
            0.31,
            0.25
        ],
        "netIncomeGrowth": [
            0.32,
            0.39
        ],
        "notes": "Consistent 25-30% YoY growth driven by GLP-1 drugs (Ozempic, Wegovy)"
    },
    "expectedScore": {
        "range": [
            88,
            95
        ],
        "grade": "A",
        "notes": "Exceptional growth trajectory, strong margins, low debt, diversified customers. AAA-rated company."
    }
}